FCARH143
Drug
Celgene Corporation
Total Payments
$2.4M
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $2.4M | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.4M | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase I trial of FCARH143 with crenigacestat (GSI) in relapsed/refractory multiple myeloma1 (FCARH143 rr MMGSI) | Celgene Corporation | $1.3M | 0 |
| Phase I trial of FCARH143 in relapsed/refractory multiple myeloma2 (FCARH143 rr MMMono) | Celgene Corporation | $1.0M | 0 |
Top Doctors Receiving Payments for FCARH143
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $2.4M | 2 |
Ad
Manufacturing Companies
- Celgene Corporation $2.4M
Product Information
- Type Drug
- Total Payments $2.4M
- Total Doctors 0
- Transactions 2
About FCARH143
FCARH143 is a drug associated with $2.4M in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2019 to 2019. In 2019, $2.4M was paid across 2 transactions to 0 doctors.
The most common payment nature for FCARH143 is "Unspecified" ($2.4M, 100.0% of total).
FCARH143 is associated with 2 research studies, including "Phase I trial of FCARH143 with crenigacestat (GSI) in relapsed/refractory multiple myeloma1 (FCARH143 rr MMGSI)" ($1.3M).